ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
License Agreement for TLANDO® Franchise in the U.S. and Canada
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 274081" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.prnewswire.com/news-releases/lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-302037718.html[/URL]</p><p></p><p></p><p><strong>SALT LAKE CITY, Jan. 18, 2024 /PRNewswire/ </strong>-- <em>Lipocine Inc. (NASDAQ: <a href="https://www.prnewswire.com/news-releases/lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-302037718.html#financial-modal" target="_blank">LPCN</a>), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders,<strong> Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which Verity Pharma will market TLANDO® in the United States and, if approved, in Canada.</strong> <strong>TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration. The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next-generation, once-daily oral product candidate for TRT.</strong></em></p><p><em></em></p><p><em>Under the terms of the agreement, Lipocine will receive from Verity Pharma a license fee of $11 million with an initial payment of $2.5 million which was received on the signing of the License Agreement, $5 million to be paid on February 1, 2024, $2.5 million to be paid no later than January 1, 2025, and $1 million to be paid no later than January 1, 2026. Lipocine will be entitled to receive up to $259 million in development and sales-based commercial milestone payments, as well as tiered royalty payments at rates ranging from 12% up to 18% on net sales of TLANDO franchise products. <strong>Under the agreement, Verity Pharma will be responsible for regulatory and marketing obligations in the U.S. and Canada, and all further development. Lipocine retains all rights to the TLANDO franchise for territories outside the U.S. and Canada, and all rights to non-TRT indications globally.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>"We are very pleased to enter this license agreement with Verity Pharma. Men's health is one of Verity Pharma's areas of focus and Verity Pharma's sales force has existing relationships with men's health prescribers. Verity Pharma is highly motivated and has the capabilities and expertise to successfully grow the TLANDO franchise without interruption in patient access to TLANDO," </strong>said Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine. <strong>"This transaction will further enable Lipocine's strategy to focus on developing treatments for CNS disorders and to add value to our non-core assets."</strong></em></p><p><em></em></p><p><em>TRT is a large and growing market with ~8M annual prescriptions in the U.S. and ~650,000 in Canada.</em></p><p><em></em></p><p><em>Raymond James acted as financial advisor to Lipocine on this transaction.</em></p></blockquote><p></p>
[QUOTE="madman, post: 274081, member: 13851"] [URL unfurl="true"]https://www.prnewswire.com/news-releases/lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-302037718.html[/URL] [B]SALT LAKE CITY, Jan. 18, 2024 /PRNewswire/ [/B]-- [I]Lipocine Inc. (NASDAQ: [URL='https://www.prnewswire.com/news-releases/lipocine-and-verity-pharma-enter-into-license-agreement-for-tlando-franchise-in-the-us-and-canada-302037718.html#financial-modal']LPCN[/URL]), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders,[B] Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which Verity Pharma will market TLANDO® in the United States and, if approved, in Canada.[/B] [B]TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration. The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next-generation, once-daily oral product candidate for TRT.[/B] Under the terms of the agreement, Lipocine will receive from Verity Pharma a license fee of $11 million with an initial payment of $2.5 million which was received on the signing of the License Agreement, $5 million to be paid on February 1, 2024, $2.5 million to be paid no later than January 1, 2025, and $1 million to be paid no later than January 1, 2026. Lipocine will be entitled to receive up to $259 million in development and sales-based commercial milestone payments, as well as tiered royalty payments at rates ranging from 12% up to 18% on net sales of TLANDO franchise products. [B]Under the agreement, Verity Pharma will be responsible for regulatory and marketing obligations in the U.S. and Canada, and all further development. Lipocine retains all rights to the TLANDO franchise for territories outside the U.S. and Canada, and all rights to non-TRT indications globally. "We are very pleased to enter this license agreement with Verity Pharma. Men's health is one of Verity Pharma's areas of focus and Verity Pharma's sales force has existing relationships with men's health prescribers. Verity Pharma is highly motivated and has the capabilities and expertise to successfully grow the TLANDO franchise without interruption in patient access to TLANDO," [/B]said Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine. [B]"This transaction will further enable Lipocine's strategy to focus on developing treatments for CNS disorders and to add value to our non-core assets."[/B] TRT is a large and growing market with ~8M annual prescriptions in the U.S. and ~650,000 in Canada. Raymond James acted as financial advisor to Lipocine on this transaction.[/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
License Agreement for TLANDO® Franchise in the U.S. and Canada
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top